Navigation Links
Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
Date:7/9/2008

COPENHAGEN, Denmark, July 9 /PRNewswire-FirstCall/ -- Summary: Genmab has completed recruitment of patients in the Phase II study of ofatumumab in combination with fludarabine and cyclophosphamide to treat front line CLL.

Genmab A/S (OMX: GEN) announced today it has completed recruitment of 56 patients in the Phase II study of ofatumumab (HuMax-CD20 (R)) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL) in previously untreated patients.

"We are pleased to complete patient enrollment in the first front line study of ofatumumab and hope to see a positive outcome for the CLL patients in this trial," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Ofatumumab is an investigational fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 molecule on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 molecule. Ofatumumab is being developed to treat CLL, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.

About the trial

Patients in this open label study will be randomized into two treatment groups of 28 patients each. Each patient will receive 6 monthly infusions of either 500 or 1000 mg of ofatumumab in combination with FC. Disease status will be measured every 4 weeks until week 24 according to National Cancer Institute Working Group Guidelines and every 3 months thereafter until disease progression or 24 months. Patients not having progressed on their disease at 24 months will be followed for disease progression at 6 month intervals until 48 months.

The objective of the study is to determine the efficacy of ofatumumab in combination with FC
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genmab Reaches Milestone in Ofatumumab Collaboration
2. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
3. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
4. Genmab Announces Updates on Phase III Cancer Studies
5. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
6. Bionomics Achieves US$1 Million Milestone Payment from Genmab
7. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
8. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
9. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
10. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
11. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN CLEMENTE, Calif. , Nov. 21, 2014 /PRNewswire/ ... Lab Coats and Performance Scrubs carried out a new ... the medical industry,s very first "limited edition" lab ... the first female professors of surgery in the world. ... departure from its unisex predecessors, with a sleek envelope ...
(Date:11/21/2014)... N.J. , Nov. 21, 2014  PTC Therapeutics, Inc. ... the 2014 Legend of Technology Award for Vision, Innovation, and ... Ph.D., Chief Executive Officer. This award recognizes an individual who ... New Jersey for several decades. ... Technology Award," stated Stuart Peltz , Ph.D., CEO of ...
(Date:11/21/2014)... -- Market research firm Kalorama information says that 2014 will ... the medical device industry.  The firm thinks the $360 ... 3% growth this year, which led firms to look ... and entrance by acquisition into new competitive zones.  The ... The Global Market for Medical Devices, 5 th ...
Breaking Medicine Technology:Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... DALLAS, Nov. 1 Death resulting from,influenza, often referred ... heart disease than among patients with any other chronic ... heart disease,patients conducted by Harris Interactive on behalf of ... with the American Heart,Association (AHA), more than one in ...
... The U.S. Department of,Health and Human Services (HHS), ... of Health of the United Mexican States today ... surveillance,prevention, and control of infectious diseases for the ... of their peoples. The Memorandum of Understanding ...
Cached Medicine Technology:Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 2Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 3Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year 4United States, Canada and Mexico Agree to Mutual Assistance During Public Health Emergencies 2
(Date:11/23/2014)... Wright & Schulte LLC recently filed 40 ... Virginia residents who allege that they developed thyroid disease, ... drinking C8 contaminated water released by the DuPont ... the C8 complaints, the plaintiffs were exposed to the ... at least one of the six water districts affected ...
(Date:11/22/2014)... Every year AlignLife clinics nationwide team ... rapid growth in the Greenville, SC area in 2014 ... AlignLife of Simpsonville will be partnering with the ... annual Toy Drive. These six offices came together to ... this year's toy drive. With so many amazing organizations ...
(Date:11/22/2014)... November 23, 2014 PrettyTailor , ... with a new big promotion. Customers can buy new ... information, customers can visit its website. , As a ... and occasion dresses. It mainly provides four types of ... dresses and flower girl dresses. It also provides a ...
(Date:11/22/2014)... Locks-Magnetic.com , one of the successful electrical locks ... for glass doors online. In addition, the company has ... Customers can get more information on its website. , ... performance. Customers who want to buy this new selection ... They also can enjoy the one-stop shopping experience. All ...
(Date:11/22/2014)... 2014 Setria® Glutathione is now ... it for use “as a therapeutically active ingredient ... the Therapeutic Goods (Listing) Notice 2014 (No. 5) ... Setria® Glutathione will be exclusivity distributed in Australia ... and imports fine chemicals to Australian manufacturers. TGA ...
Breaking Medicine News(10 mins):Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... of it kind to establish a link between sleep and ... have higher insulin resistance, and a harder time controlling the ... Diabetes Care , suggest that poor sleep may contribute ... quality in people with diabetes was associated with worse control ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... supplements and teas for infants is a surprisingly common practice, ... not be safe for babies. The study, conducted ... 10 percent of babies are given botanical supplements or teas ...
... News) -- Infants who aren,t breast-fed may experience long-term health ... body composition (fat mass vs. lean body mass) and blood ... for the first four months of life, while infants in ... formula: a lower-protein formula with 1.8 grams (g) of protein ...
... DENVER, CO, MAY 2, 2011 Two scientists who ... been chosen to receive the 2011 March of Dimes ... OBE, DSc, FRS, professor of Human Genetics, Southampton University ... Laboratory, Salisbury, England and David C. Page, MD, director, ...
... ROCHESTER, Minn. -- By all counts, the 54-year-old man ... Minnesota would likely have died. He,d suffered a heart ... and a series of shocks with a defibrillator, the ... this particular instance of cardiac arrest ( http://www.mayoclinic.org/heart-attack/ ), ...
... May 2 (HealthDay News) -- Obese pregnant women may have ... new research suggests. Researchers tested the blood of 30 ... and had a body-mass index (BMI) of more than 30 ... of 20 to 25. Obese women had fewer immune ...
Cached Medicine News:Health News:Insomnia linked to high insulin resistance in diabetics 2Health News:Study Questions Giving Babies Botanical Supplements, Teas 2Health News:Study Questions Giving Babies Botanical Supplements, Teas 3Health News:Breast-feeding May Influence Long-Term Health: Study 2Health News:Mayo Clinic CPR efforts successful on man with no pulse for 96 minutes 2
DePuy 2 Bone Cement is a unique fast-set digital cement that is the excellent choice for small joint procedures such as the patella, glenoid or other extremity joints....
... Sir John Charnley and CMW, Inc. ... develop bone cements exclusively for orthopaedic ... 40 years of performance and excellence ... offers one of the first proven ...
... Blood Flow Analyzer is a fast, clinically ... diagnosis of low and normal-tension glaucoma., ,The ... fast, clinically proven measurement that improves detection ... the management of glaucoma, and detection of ...
Occu-Flo Plugs Offer: , Easy Insertion , A polished, smooth, transparent finish which creates immediate patient comfort and adaptation , High tolerance by patients , No discomfort should removal be ...
Medicine Products: